Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Smith & Nephew plc (SN.L)
Watford, GB
Smith & Nephew plc, along with its subsidiaries, operates globally as a developer, manufacturer, marketer, and seller of medical technology. Its orthopaedic division offers knee implants for replacement procedures and hip implants for joint reconstruction. This segment also provides trauma and extremities products, including internal and external fixation devices crucial for stabilizing severe fractures and correcting deformities. In the sports medicine field, the company furnishes surgeons with comprehensive joint repair solutions. These encompass specialized instruments, advanced technologies, and implants necessary for minimally invasive joint surgeries, addressing soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. Additionally, its arthroscopic enabling technologies support surgical visualization and intervention inside joints, comprising fluid management equipment, high-definition cameras, digital image capture systems, scopes, light sources, and monitors. It also supplies radiofrequency, electromechanical, and mechanical tissue resection devices, along with hand instruments for removing damaged tissue, and provides ear, nose, and throat (ENT) solutions. Furthermore, Smith & Nephew delivers sophisticated advanced wound management solutions. This category features products for the treatment and prevention of acute and chronic wounds, including leg, diabetic, and pressure ulcers, burns, and post-operative wounds. Its offerings extend to advanced wound bioactives, incorporating biologics and other active technologies for debridement, dermal repair, and regeneration, as well as regenerative medicine products like skin, bone graft, and articular cartilage substitutes. The advanced wound devices portfolio includes traditional and single-use negative pressure wound therapy systems, alongside hydrosurgery devices. Primarily serving healthcare providers, Smith & Nephew plc was founded in 1856 and maintains its corporate headquarters in Watford, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -3.22% | -2.29% | -18.99% | -11.44% | -10.29% | +3.20% | -7.57% | -27.48% | -5.20% | +339.56% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | +1 |
| Buy | 5 | 0 |
| Hold | 10 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+8.3% Q4'25: +17.4% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+55.3% ★ Q4'25: +274.3% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%+15.6% ★ Q4'25: +17.8% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%+16.3% ★ Q4'25: +17.4% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%+10.2% ★ Q4'25: +22.8% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%-0.4% ★ Q4'25: -0.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×2.07× Q4'25: 0.94× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 16 Rev. Ana. 16 EPS Ana. |
Dec 2027 17 Rev. Ana. 16 EPS Ana. |
Dec 2028 9 Rev. Ana. 15 EPS Ana. |
Dec 2029 14 Rev. Ana. 14 EPS Ana. |
Dec 2030 8 Rev. Ana. 14 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.63B
est: 4.64B (0.0%)
|
4.67B
est: 4.66B (+0.2%)
|
4.77B
est: 4.75B (+0.3%)
|
4.90B
est: 4.89B (+0.4%)
|
5.14B
est: 4.95B (+3.7%)
|
4.56B
est: 4.59B (-0.7%)
|
5.21B
est: 3.86B (+35.0%)
|
5.21B
est: 5.21B (+0.1%)
|
5.22B
est: 4.30B (+21.3%)
|
5.22B
est: 5.28B (-1.3%)
|
5.55B
est: 5.51B (+0.8%)
|
5.81B
est: 5.78B (+0.6%)
|
6.29B
est: 6.13B (+2.7%)
|
6.59B
6.53B – 6.65B
+7.5% YoY
|
6.96B
6.81B – 7.06B
+5.7% YoY
|
7.35B
7.24B – 7.44B
+5.6% YoY
|
7.78B
7.66B – 7.87B
+5.8% YoY
|
8.31B
8.18B – 8.40B
+6.8% YoY
|
| EBITDA |
1.12B
est: 970.54M (+14.9%)
|
1.27B
est: 975.55M (+29.8%)
|
1.39B
est: 995.06M (+40.0%)
|
1.29B
est: 1.02B (+25.8%)
|
1.34B
est: 1.04B (+28.8%)
|
866.00M
est: 961.37M (-9.9%)
|
1.24B
est: 757.40M (+64.0%)
|
1.24B
est: 1.09B (+13.9%)
|
874.00M
est: 843.58M (+3.6%)
|
874.00M
est: 1.11B (-21.0%)
|
956.00M
est: 1.15B (-17.1%)
|
1.24B
est: 1.21B (+2.3%)
|
1.61B
est: 1.28B (+25.4%)
|
1.38B
1.37B – 1.39B
+7.5% YoY
|
1.46B
1.43B – 1.48B
+5.7% YoY
|
1.54B
1.52B – 1.56B
+5.6% YoY
|
1.63B
1.60B – 1.65B
+5.8% YoY
|
1.74B
1.71B – 1.76B
+6.8% YoY
|
| EBIT |
622.00M
est: 506.15M (+22.9%)
|
1.13B
est: 508.76M (+122.1%)
|
946.00M
est: 518.94M (+82.3%)
|
852.00M
est: 533.50M (+59.7%)
|
818.00M
est: 540.84M (+51.2%)
|
321.00M
est: 501.37M (-36.0%)
|
679.00M
est: 350.19M (+93.9%)
|
679.00M
est: 568.54M (+19.4%)
|
326.00M
est: 390.04M (-16.4%)
|
326.00M
est: 576.97M (-43.5%)
|
429.00M
est: 601.28M (-28.7%)
|
657.00M
est: 630.58M (+4.2%)
|
1.02B
est: 669.15M (+53.0%)
|
719.16M
713.23M – 725.59M
+7.5% YoY
|
760.43M
743.33M – 770.47M
+5.7% YoY
|
802.85M
790.37M – 811.79M
+5.6% YoY
|
849.33M
836.13M – 858.79M
+5.8% YoY
|
906.88M
892.78M – 916.98M
+6.8% YoY
|
| Net Income |
410.00M
est: 711.01M (-42.3%)
|
784.00M
est: 708.54M (+10.7%)
|
767.00M
est: 760.17M (+0.9%)
|
663.00M
est: 829.07M (-20.0%)
|
600.00M
est: 854.99M (-29.8%)
|
448.00M
est: 546.75M (-18.1%)
|
524.00M
est: 536.17M (-2.3%)
|
524.00M
est: 720.20M (-27.2%)
|
223.00M
est: 563.41M (-60.4%)
|
223.00M
est: 689.55M (-67.7%)
|
263.00M
est: 712.79M (-63.1%)
|
412.00M
est: 725.87M (-43.2%)
|
638.11M
est: 865.66M (-26.3%)
|
959.25M
937.32M – 985.64M
+10.8% YoY
|
1.07B
1.02B – 1.13B
+11.9% YoY
|
1.19B
1.16B – 1.21B
+10.7% YoY
|
1.26B
1.23B – 1.27B
+5.6% YoY
|
1.33B
1.31B – 1.35B
+6.3% YoY
|
| SGA |
2.64B
est: 2.15B (+22.7%)
|
2.03B
est: 2.16B (-6.3%)
|
2.15B
est: 2.21B (-2.5%)
|
2.19B
est: 2.27B (-3.6%)
|
2.31B
est: 2.30B (+0.6%)
|
2.56B
est: 2.13B (+20.2%)
|
2.39B
est: 1.86B (+28.5%)
|
2.39B
est: 2.42B (-1.0%)
|
2.44B
est: 2.08B (+17.3%)
|
2.44B
est: 2.45B (-0.7%)
|
2.60B
est: 2.56B (+1.8%)
|
2.65B
est: 2.68B (-1.1%)
|
2.95B
est: 2.84B (+3.8%)
|
3.06B
3.03B – 3.08B
+7.5% YoY
|
3.23B
3.16B – 3.28B
+5.7% YoY
|
3.41B
3.36B – 3.45B
+5.6% YoY
|
3.61B
3.55B – 3.65B
+5.8% YoY
|
3.86B
3.80B – 3.90B
+6.8% YoY
|
| EPS |
0.46
est: 0.81 (-43.5%)
|
0.88
est: 0.81 (+8.4%)
|
0.88
est: 0.87 (+1.0%)
|
0.76
est: 0.95 (-20.0%)
|
0.69
est: 0.98 (-29.6%)
|
0.51
est: 0.63 (-18.6%)
|
0.60
est: 0.61 (-1.9%)
|
0.60
est: 0.83 (-27.3%)
|
0.25
est: 0.64 (-61.1%)
|
0.25
est: 0.79 (-68.4%)
|
0.31
est: 0.82 (-62.4%)
|
0.47
est: 0.83 (-43.5%)
|
0.74
est: 0.99 (-25.4%)
|
1.10
1.07 – 1.13
+10.8% YoY
|
1.23
1.17 – 1.30
+11.9% YoY
|
1.36
1.33 – 1.38
+10.7% YoY
|
1.44
1.41 – 1.46
+5.6% YoY
|
1.53
1.50 – 1.55
+6.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-01 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Deepak S. Nath | Chief Executive Officer & Director | 3M | — |
| John Terence Rogers | Chief Financial Officer & Executive Director | 2M | male |
| Charles Reynolds | Head of Corporate Communication | — | male |
| Elga Lohler | Chief Human Resources Officer | — | female |
| Emily Heaven | Head of Investor Relations | — | — |
| Helen Barraclough | Group General Counsel & Company Secretary | — | female |
| Paul Connolly | President of Global Operations | — | male |
| Ajay Dhankhar | Chief Corporate Development & Strategy Officer | — | male |
| Vasant Padmanabhan | President Research & Development, ENT and Emerging Markets | — | — |
| Alison Parkes | Chief Compliance Officer & Compliance APAC | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SN.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
